Donor Natural Killer Cells, Cyclophosphamide, and Etoposide in Treating Children and Young Adults With Relapsed or Refractory Solid Tumors
Public ClinicalTrials.gov record NCT03420963. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
Ex-Vivo Expanded Allogeneic NK Cells for the Treatment of Solid Tumors of Pediatric Origin in Children and Young Adults
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This phase I trial studies the side effects and best dose of cord blood-derived expanded allogeneic natural killer cells (donor natural killer \[NK\] cells) and how well they work when given together with cyclophosphamide and etoposide in treating children and young adults with solid tumors that have come back (relapsed) or that do not respond to treatment (refractory). NK cells, white blood cells important to the immune system, are donated/collected from cord blood collected at birth from healthy babies and grown in the lab. Drugs used in chemotherapy, such as cyclophosphamide and etoposide, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving NK cells together with cyclophosphamide and etoposide may work better in treating children and young adults with solid tumors.
Study identification
- NCT ID
- NCT03420963
- Recruitment status
- Terminated
- Study type
- Interventional
- Phase
- Phase 1
- Enrollment
- 12 participants
Conditions and interventions
Conditions
- Recurrent Cutaneous Melanoma
- Recurrent Lip and Oral Cavity Carcinoma
- Recurrent Malignant Endocrine Neoplasm
- Recurrent Malignant Female Reproductive System Neoplasm
- Recurrent Malignant Male Reproductive System Neoplasm
- Recurrent Malignant Mesothelioma
- Recurrent Malignant Neoplasm of Multiple Primary Sites
- Recurrent Malignant Oral Neoplasm
- Recurrent Malignant Pharyngeal Neoplasm
- Recurrent Malignant Skin Neoplasm
- Recurrent Malignant Soft Tissue Neoplasm
- Recurrent Malignant Solid Neoplasm
- Recurrent Malignant Thyroid Gland Neoplasm
- Recurrent Malignant Urinary System Neoplasm
- Refractory Cutaneous Melanoma
- Refractory Malignant Bone Neoplasm
- Refractory Malignant Endocrine Neoplasm
- Refractory Malignant Female Reproductive System Neoplasm
- Refractory Malignant Male Reproductive System Neoplasm
- Refractory Malignant Mesothelioma
- Refractory Malignant Neoplasm of Multiple Primary Sites
- Refractory Malignant Oral Neoplasm
- Refractory Malignant Pharyngeal Neoplasm
- Refractory Malignant Skin Neoplasm
- Refractory Malignant Soft Tissue Neoplasm
- Refractory Malignant Solid Neoplasm
- Refractory Malignant Thyroid Gland Neoplasm
- Refractory Malignant Urinary System Neoplasm
Interventions
- Cord Blood-derived Expanded Allogeneic Natural Killer Cells Biological
- Cyclophosphamide Drug
- Etoposide Drug
Biological · Drug
Eligibility (public fields only)
- Age range
- 12 Months to 40 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Aug 30, 2018
- Primary completion
- Feb 25, 2026
- Completion
- Feb 25, 2026
- Last update posted
- Mar 19, 2026
2018 – 2026
United States locations
- U.S. sites
- 1
- U.S. states
- 1
- U.S. cities
- 1
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| M D Anderson Cancer Center | Houston | Texas | 77030 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT03420963, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Mar 19, 2026 · Synced Sep 4, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT03420963 live on ClinicalTrials.gov.